Abstract

Synchrony Financial will report third-quarter 2026 results on October 20, 2026, Pre-MKt; the market anticipates revenue of 4.84 billion US dollars and adjusted EPS of 2.42, while investors monitor credit costs, funding dynamics, purchase volume momentum, and margin resilience into year-end.

Market Forecast

Consensus points to third-quarter revenue of 4.84 billion US dollars, up 3.05% year over year, and adjusted EPS of 2.42, up 8.96% year over year; EBIT is projected at 2.35 billion US dollars, a 10.46% decline year over year. Forecasts for gross margin or net margin are not provided. The core book remains anchored by “Thrift / Savings and Loan Institutions,” which generated 2.52 billion US dollars last quarter and should benefit from stable net interest income and disciplined expense control, alongside continued partner wins. The most promising growth vector is health and wellness financing under CareCredit, where recent integrations and partnerships are expanding distribution; while segment revenue was not disclosed, purchase volumes in closely tied co-branded and specialty programs accelerated earlier this year and point to healthy underlying demand.

Last Quarter Review

Synchrony Financial posted revenue of 4.61 billion US dollars (+1.92% year over year), gross margin not disclosed, GAAP net profit attributable to shareholders of 885.00 million US dollars, net profit margin of 35.16%, and adjusted EPS of 2.59 (+3.60% year over year). A key highlight was the outperformance versus market expectations on both revenue and EPS, reflecting resilient net interest income and better-than-anticipated operating leverage. Main business highlights: “Thrift / Savings and Loan Institutions” contributed 2.52 billion US dollars last quarter, while group revenue grew 1.92% year over year as purchase activity and financing originations remained supportive.

Current Quarter Outlook

Main business performance drivers

The principal revenue engine is the lending book and related net interest income, which is paced by receivables growth, funding costs, and the trajectory of charge-offs and delinquencies. Into the third quarter, the setup is a balancing act: purchase volumes and receivable growth sustain asset yields, while deposit and wholesale funding costs continue to normalize. The market’s revenue expectation of 4.84 billion US dollars implies incremental top-line improvement relative to the prior quarter, while the EPS estimate of 2.42 embeds conservative assumptions on credit normalization and operating expenses. Portfolio quality metrics remain the swing factor: even modest stabilization in early-stage delinquencies would bolster the path to an earnings beat, whereas faster roll rates from early- to late-stage delinquency buckets could keep credit costs elevated. The company’s proven ability to secure and deepen merchant partnerships supports receivable formation and fee income, which, combined with measured operating expense growth, can preserve operating leverage even as funding spreads fluctuate. Taken together, investors should watch the cadence of net charge-off rates, reserve builds or releases, and commentary on funding duration and deposit pricing discipline for signals on earnings durability into the holiday quarter.

Most promising business: CareCredit and embedded financing footprint

CareCredit’s ecosystem continues to expand through embedded financing arrangements with health, wellness, and veterinary platforms, with recent integrations designed to streamline patient and pet owner approvals at the point of need. A strategic integration into an AI-enabled veterinary practice management platform with a footprint exceeding 1,000 hospitals brings financing options directly into clinician workflows; internal data indicate roughly 85% of these clinics were already enrolled, which suggests substantial room for increased utilization per location as integration improves attach rates. Separately, new partnerships targeting health and wellness service providers, including technology-enabled payment facilitators, broaden merchant acquisition funnels and may lower onboarding frictions, supporting application throughput and approval conversions. Earlier this year, the company also highlighted accelerating purchase activity across co-branded and specialty programs, with co-branded purchases showing double-digit year-over-year expansion, indicating healthy spend propensity among engaged cardholders. For the quarter at hand, the focus is not only on origination volume but also on yield sustainability and loss seasoning in newer cohorts; early performance data from recent vintages, as well as any updates on promotional financing balances and repricing, will be critical for extrapolating unit economics. Over the medium term, the combination of expanded distribution via integrations and targeted underwriting could lift both originations and overall program profitability, even if top-of-funnel consumer demand remains mixed.

Stock-price drivers this quarter

The largest driver for the shares around the print is likely to be credit costs versus expectations, specifically the net charge-off rate and incremental allowance builds. Investors will closely parse early- and late-stage delinquency migration, roll rates, and any commentary on borrower payment behavior heading into the peak shopping season, as these shape forward loss curves and the reserve outlook. A second key factor is margin resilience, where funding dynamics—deposit betas, term funding mix, and duration—interact with asset yields to determine net interest spread; any indication of easing funding pressures or improved asset mix toward higher-yielding receivables can bolster the margin narrative. A third factor is revenue trajectory from merchant and ecosystem partnerships, particularly evidence of uplift from new integrations in health and wellness financing and continued strength in co-branded programs; tangible signs of partner expansion or higher spend per active account can drive positive estimate revisions. Capital return remains a supporting pillar: the recently increased quarterly dividend to 0.34 per share and an active approach to capital deployment provide a cushion for total shareholder return if growth temporarily moderates. Finally, policy and regulatory rhetoric—such as intermittent debate about credit card rate policies earlier in the year—can introduce episodic volatility; any company commentary that contextualizes potential impacts and underscores risk management frameworks may help narrow the policy overhang embedded in valuation multiples.

Analyst Opinions

Bullish views are in the majority among explicit rating updates observed year-to-date, with a roughly 100% to 0% split versus bearish calls; several well-followed firms have reiterated constructive stances and price targets that sit above the current share price. Evercore ISI maintained an Outperform rating while adjusting its price target to 80.00 US dollars during the period, emphasizing earnings durability supported by credit normalization and partner momentum. Seaport Global highlighted upside potential with a target of 93.00 US dollars, pointing to operating leverage and continued spend strength in co-branded and specialty programs as potential catalysts for estimate revisions. Additional datapoints across the coverage universe indicate an average rating skewing toward overweight and a mean price target clustered around the high-80s in US dollars, reinforcing the constructive bias heading into the print. The bullish cohort generally expects the company to navigate credit normalization without a step-function increase in provisioning, to maintain healthy net interest income despite funding normalization, and to show evidence that embedded financing partnerships are translating into sustained origination and spend growth. In this framework, the quarter’s key proof points are credit metrics that track in-line or slightly better than feared, stable or improving funding spreads, and commentary suggesting the partner pipeline will continue to support receivables growth into the holiday period. Should those elements come through, bullish analysts argue there is scope for a modest EPS beat against the 2.42 consensus and for valuation to re-rate toward peer averages implied by the prevailing price target range.